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Background. An elevated platelet count is often associated with malignancies, and it has been confirmed as an adverse prognostic
factor in various cancers including early stage breast cancer. We sought to determine if thrombocytosis is also a prognostic factor
in metastatic breast cancer. Patients and Methods. The records of 165 metastatic breast cancer patients with complete follow-up
that had thrombocytosis or normal platelet counts were reviewed. Kaplan-Meier curves were constructed, and the survivals of
the two groups were compared using the LogRank test. A Cox regression analysis was used to determine if thrombocytosis is an
independent factor for overall and progression free survival. Results. There was a statistically significant difference in overall and
progression free survival favoring the normal platelets group (LogRank test 𝑃 = 0.038 and 0.008, resp.). Thrombocytosis remained
a significant adverse prognostic factor in multivariate analysis. Other independent prognostic factors for overall survival included
age, ER/PR status, and grade. Conclusion. Thrombocytosis represents an independent adverse prognostic factor in patients with
metastatic breast cancer. Thus metastatic breast cancer joins a range of cancers in which this easily measurable value can be used
for clinical prognostication. Further use as a predictive value for specific treatments has a rationale and deserves to be investigated.
1. Introduction
Platelets are important cellular particles for hemostasis and
vascular integrity.They are produced from bonemarrow pre-
cursor cells, megakaryocytes. Abnormalities in their normal
circulating number either in the form of thrombocytosis or
thrombocytopenia are associated with many pathologic con-
ditions [1]. Cytokines that stimulate thrombopoiesis are often
elevated in cancer, and as a result, various cancers have been
associated with thrombocytosis. In addition thrombocytosis
has been found to be an adverse prognostic factor in many
types of common cancers.
Breast cancer is the most common female malignancy.
When localized, it is treated with surgery and often with
adjuvant therapies to decrease the risk of local or systemic
recurrences [2]. Both adjuvant therapies and therapies in
the metastatic disease setting are guided by biologic charac-
teristics such as hormone receptors and growth factor Her-
2 expression. These characteristics possess also prognostic
information, but additional markers are needed to further
promote prognostication of breast cancer. In early stage breast
cancer patients undergoing chemotherapy in five clinical tri-
als of theAustrian Breast andColorectal Cancer StudyGroup,
pretreatment thrombocytosis was an independent prognostic
factor for overall survival and breast cancer-specific survival
[3].We investigated if pretreatment high thrombocyte counts
provide prognostic information in patients with metastatic
breast cancer.
2. Patients and Methods
Case records of women with breast cancer treated in the
Medical Oncology Department of the University Hospital of
Lausanne over the last 12 years were retrospectively reviewed.
Further information was collected from charts of patients
with metastatic disease at diagnosis or at any later time of
their disease history and with complete follow-up. Follow-
up was considered complete if a patient was followed till her
death or was seen within the last 6 months from data collec-
tion. Data on patients’ age, biologic characteristics of tumors,
time from original diagnosis to metastatic disease, and site(s)
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of metastases were recorded. Platelet number on diagnosis of
metastatic breast cancer (before the start of any therapy for
metastatic disease) was evaluated in 179 patients for whom
there were complete follow-up data. Overall survival (OS)
was defined as the interval from the date of diagnosis of
metastatic disease to death. Progression free survival (PFS)
was defined as the interval from the date of diagnosis of
metastatic disease to disease progression or death, whichever
happened first. Her-2/Neu positivity was defined as 3+ by
immunohistochemistry (IHC) or FISH amplification accord-
ing to standard criteria [4]. For the purposes of the current
study Her-2 was considered negative if IHC was 2+ and
FISH had not been performed. In the normal platelet count
group patients with platelet counts of 150 to 350 × 109/L
were included. In the thrombocytosis group patients with
platelet counts of >350 × 109/L were included. Survival plots
of patients with normal platelet counts and thrombocytosis
were constructed using the Kaplan-Meier method and were
compared using the LogRank test [5]. The 𝜒2 test was used
to evaluate differences in clinical and biologic characteristics
in the two groups [6]. A Cox regression proportional hazard
multivariate analysis was performed to identify statistically
significant factors associated with overall and progression
free survival. All P values were considered to be significant
at the level of 𝑃 < 0.05. Statistical calculations were
performed with online tools available from the Technical
University of Denmark (http://www.iscc-serv2.imm.dtu.dk/)
and a noncommercial site (http://www.statpages.org/).
3. Results
Among 215 patients with metastatic breast cancer followed
in our department during the period of the last 12 years,
179 patients had complete follow-up. Fourteen patients had
thrombocytopenia at diagnosis and were excluded from
further analysis. From the remaining 165 patients, 135 (81.8%)
had normal platelet counts at diagnosis of metastatic disease,
and 30 (18.2%) had thrombocytosis (Table 1). The median
platelet count of the whole group of patients was 261 × 109/L
(range 154–694). The median platelet count in the normal
platelet group was 241 × 109/L (range 154–349) and in the
thrombocytosis group was 407 × 109/L (range 354–694). The
median age of thewhole groupwas 62 years old (range 31–92).
110 patients had died, and 55 patients were alive at last follow-
up. The median follow-up of patients alive was 25 months
and the mean 30.14 months [95% confidence interval (CI)
23.55–36.74]. The median age of the patients with normal
counts was 62 years old (range 31–92) and of those with
thrombocytosiswas 66 years old (range 44–85). In the normal
platelets group 92 patients had died, and 43 patientswere alive
with a median follow-up of 33 months (mean 33.88 months,
95%CI 25.95–41.82). In the thrombocytosis group 18 patients
had died and 12 patients were alive with a median follow-
up of 12.5 months (mean 16.75 months, 95% CI 9.33–24.17).
Other baseline characteristics of patients and their disease
are given in Table 1. There were no statistically significant
differences in the proportion of patients in the two groups
regarding the hormone receptors status, the Her-2 status, the
grade of the tumors, whether metastatic disease was confined
to bone or had also spread to other sites, and the therapy
patients had received as first line metastatic treatment. For
patients that had initially been diagnosed with local disease
(𝑛 = 98), there was no difference between the normal
platelet and thrombocytosis group in the percentage of
patients who received no adjuvant treatment or only adjuvant
hormonotherapy and those that had chemotherapy included
in their adjuvant treatment (𝑃 = 0.87). More patients in
the thrombocytosis group hadmetastatic disease at diagnosis
(70% versus 34.1% in the normal platelets group,𝑃 = 0.0003).
The median overall survival of patients that had died in
the whole group (110 of 165 patients) was 24 months, and
the mean was 28.2 months (95% CI 23.7–32.7). The median
overall survival (OS) of patients that had died in the group
with normal platelet counts was 26 months (range 1–115
months) and the mean was 30.08 months (95% CI 24.97–
35.19) while the median OS of patients with thrombocytosis
was 12.5 months (range 2–54 months) and the mean was 18.6
months (95% CI 10.95–26.27). OS was 50% (95% CI 41.6–
58.3%) and 26% (95% CI 14–44.6%) at 3 years in the normal
and thrombocytosis group, respectively. There were no long
term survivors at 5 year in the group with thrombocytosis
while in the normal platelets group 5-years survival was 22%
(95% CI 15.35–29.2%).
There was a statistically significant difference of the
overall survival between the two groups (LogRank test
𝑃 = 0.038) (Figure 1). In the multivariate Cox regression
analysis, increasing age, higher grade, ER/PR negativity, and
thrombocytosis were statistically significantly associatedwith
reduced overall survival while Her-2 status, the presence of
metastases at diagnoses, the location of metastatic disease,
and the administration and type of first line metastatic
treatment were not (Table 2).
There was also a statistically significant difference of the
progression free survival between the two groups (LogRank
test 𝑃 = 0.008) (Figure 2). In this instance the multivariate
Cox regression analysis showed that higher grade, ER/PR
negativity, the presence of metastases at diagnoses, and
thrombocytosis were statistically and significantly associated
with reduced progression free survival while age, Her-2 sta-
tus, the location of metastatic disease, and the administration
and type of first line metastatic treatment were not (Table 3).
4. Discussion
An elevated platelet count may have various causes and
is either primary due to essential thrombocytosis or other
myeloproliferative disorders or secondary to infection,
trauma or surgery, iron deficiency, or malignancy. When
other conditions are excluded, about 40% of patients with
thrombocytosis of more than 400 × 109/L have been found
to harbor an occult cancer [7]. In this retrospective study
we have shown for the first time that thrombocytosis is
associated with decreased OS and PFS in patients with
metastatic breast cancer. In our cohort of 165 patients there
were no significant differences between the two groups with
normal platelets and thrombocytosis in the age of patients,
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Table 1: Characteristics and outcome of patients in the series. Column “All patients” includes the whole series of patients with normal platelets
or thrombocytosis. 𝜒2 test between the group with normal platelet count and the group with thrombocytosis is shown. Wherever there are
more than two categories, the grouping of the comparison is mentioned in the same column. Her-2 was defined as positive if 3+ by IHC or
amplified by FISH and negative if 1+ by IHC or 2+ by IHC and FISH not amplified or not performed.
All patients normal thrombocytosis 𝜒2
Number (%) 165 (100) 135 (81.8) 30 (18.2)
Age at diagnosis of metastatic disease
Median (range) 62 (31–92) 62 (31–92) 66 (44–85)
>65 years 70 (42.4) 54 (40) 16 (53.3) 𝑃 = 0.17
≤65 years 95 (57.6) 81 (60) 14 (46.7)
ER/PR Positive versus negative
𝑃 = 0.69
Positive (either or both) 126 (76.4) 102 (75.5) 24 (80)
Negative (both) 37 (22.4) 31 (23) 6 (20)
Unknown 2 (1.2) 2 (1.5) 0
Her-2 Positive versus negative
𝑃 = 0.35
Positive 35 (21.2) 27 (20) 8 (26.7)
Negative 107 (64.9) 90 (66.7) 17 (56.7)
Unknown or ambiguous 23 (13.9) 18 (13.3) 5 (16.6)
Grade III versus I and II
𝑃 = 0.42
I 10 (6.1) 8 (6) 2 (6.7)
II 66 (40) 55 (40.7) 11 (36.6)
III 67 (40.6) 52 (38.5) 15 (50)
Unknown 22 (13.3) 20 (14.8) 2 (6.7)
Metastatic at diagnosis
Yes 67 (40.6) 46 (34.1) 21 (70) 𝑃 = 0.0003
No 98 (59.4) 89 (65.9) 9 (30)
Sites of metastases Bone only versus other
𝑃 = 0.81
Bone 41 (24.9) 34 (25.2) 7 (23.3)
Soft tissue 21 (12.7) 20 (14.8) 1 (3.3)
Parenchymal 38 (23) 34 (25.2) 4 (13.4)
Multiple sites 65 (39.4) 47 (34.8) 18 (60)
1st metastatic treatment
None or hormonotherapy 74 (44.8) 63 (46.7) 11 (36.7) 𝑃 = 0.32
Chemotherapy 91 (55.2) 72 (53.3) 19 (63.3)
Adjuvant treatment
None or hormonotherapy 52 (53.1) 47 (52.8) 5 (55.6) 𝑃 = 0.87
Chemotherapy 46 (46.9) 42 (47.2) 4 (44.4)
biologic characteristics of their cancer such as ER/PR and
Her-2 expression and grade, and no significant difference
on whether they had bone only or other sites of metastases.
Patients with thrombocytosis weremore likely to havemetas-
tases at diagnosis with breast cancer while the normal platelet
group wasmore likely to have developedmetastatic disease at
a later time in the course of their disease (𝑃 = 0.0003). This
may be due to a more aggressive biology of cases with throm-
bocytosis that favors earlier metastases development. In
the multivariate analysis, increasing age, hormonal receptors
negativity, and higher grade were associated together with
thrombocytosis with decreased overall survival. Her-2 was
not an independent predictor of overall or progression free
survival possibly due to the fact that, for a significantminority
of patients (23 out of 165), Her-2 status was unknown or
ambiguous (meaning that it was 2+ by IHC, and no FISH
was performed) or due to treatment with anti-Her-2 targeted
therapies which improve the outcome of these patients [8, 9].
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Table 2: Multivariate Cox regression analysis of parameters possibly related to overall survival of metastatic breast cancer patients.
Variable Hazard ratio 95% confidence interval P value
Lower limit Upper limit
Thrombocytosis 1.75 1.01 3.02 0.043
Age 1.02 1.011 1.044 0.0009
ER/PR status 0.50 0.31 0.78 0.0028
Her-2 status 0.93 0.57 1.51 0.77
Grade 1.48 0.98 2.21 0.05
Metastatic at diagnosis 0.82 0.54 1.25 0.36
Site of metastasis (bone only versus other) 0.79 0.48 1.29 0.34
1st metastatic treatment (none or hormonotherapy versus chemotherapy) 1.47 0.92 2.33 0.10
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Figure 1: Kaplan-Meier overall survival curves in months from
the diagnosis of metastatic disease of patients with normal platelet
counts (150–350 × 109/L) versus patients with thrombocytosis.
LogRank test 𝑃 = 0.038.
Bone only disease also was not a significant prognostic factor
in themultivariate analysis possibly due to its associationwith
other parameters and notably hormone receptor status.
Other investigators have previously detected an asso-
ciation of thrombocytosis with worse outcome in patients
with early breast cancer [3]. This retrospective study is the
most extended series addressing the subject in any type of
cancer and included 4,300 patients that had been treated in
five randomized trials of the Austrian Breast and Colorectal
Cancer Study Group. In this report thrombocytosis was
defined as platelets more than 400 × 109/L and was present
in 3.7% of patients. The estimated overall survival of patients
with thrombocytosis was 71 months versus 99.5 months in
patients without thrombocytosis. Thrombocytosis was an
independent prognostic factor for overall survival and breast
cancer related survival but not for disease-free survival [3].
Thrombocytosis appears to be a universal marker of
adverse outcomes in cancer. Its association with worse
oncologic outcomes has been also reported in esophageal
squamous cell carcinoma [10], gastric adenocarcinoma [11],
renal cell carcinoma [12], ovarian carcinoma [13], and other
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Figure 2: Kaplan-Meier progression free survival curves in months
from the diagnosis of metastatic disease of patients with normal
platelet counts (150–350 × 109/L) versus patients with thrombocy-
tosis. LogRank test 𝑃 = 0.008.
cancers [14, 15]. In patients with esophageal squamous cell
carcinoma, thrombocytosis, defined as platelets more than
293 × 109/L which was the mean plus 1 standard deviation
of a healthy control group, was present in 21% of patients
andwas a significant independent prognostic factor [10].This
associationwas statistically significant for patients with stages
III and IV but not for stages I and II disease. In gastric
adenocarcinoma patients that had undergone gastrectomy
with negative margins, thrombocytosis (defined as platelets
more than 400 × 109/L in this study) was associated with
worse survival and was a strong predictor specifically of
hematogenous metastasis but not of locoregional recurrence
or peritoneal seeding [11]. In another series of gastric can-
cer patients, thrombocytosis was associated with worse 1-
year and 3-year survival and was positively correlated with
depth of tumor invasion [16]. A third example of tumor
where thrombocytosis has prognostic significance is renal
cell carcinoma. Metastatic renal carcinoma patients with
thrombocytosis (defined as platelets more than 400 × 109/L
at least in one occasion during their disease) had a mean
survival of 92 months compared with 151 months in patients
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Table 3: Multivariate Cox regression analysis of parameters possibly related to progression free survival of metastatic breast cancer patients.
Variable Hazard ratio 95% confidence interval P value
Lower limit Upper limit
Thrombocytosis 2.00 1.26 3.17 0.0031
Age 1.00 0.9975 1.023 0.21
ER/PR status 0.59 0.38 0.91 0.018
Her-2 status 1.027 0.65 1.61 0.90
Grade 1.54 1.06 2.22 0.021
Metastatic at diagnosis 0.61 0.42 0.89 0.012
Site of metastasis (bone only versus other) 0.82 0.52 1.30 0.40
1st metastatic treatment (none or hormonotherapy versus chemotherapy) 1.37 0.87 2.16 0.17
with normal platelets [12]. This difference was significant in
multivariate Cox analysis.
Thrombocytosis (defined as platelets more than 450 ×
109/L) was associated with more advanced stage and higher
preoperative Ca-125 in ovarian carcinoma [13]. In addition
the median overall survival in patients with thrombocytosis
was 2.62 years while in the group with normal platelets it
was 4.65 years (𝑃 < 0.001). In another study in ovarian
cancer, thrombocytosis (defined as platelets more than 400 ×
109/L) was also associated with advanced stage and grade and
reduced overall survival [17].
Thrombocytosis was significantly correlated with plasma
levels of IL-6 in patients with ovarian carcinoma [13]. In
mouse models bearing human ovarian cancer, human IL-
6 was found to stimulate hepatocytes via the IL-6 receptor
to produce thrombopoietin. Thus a model was proposed
according to which ovarian cancer tumor cells produce IL-6
which stimulates the liver to produce thrombopoietin, finally
resulting in increased thrombopoiesis through stimulation
of megakaryocyte progenitors in the bone marrow [13]. In
other cancers IL-6 may also play a similar role in producing
thrombocytosis. In renal carcinoma the majority of cases
examined were positive for IL-6 by immunohistochemistry
[18]. Serum levels of IL-6 were elevated in prostate cancer
patients with more advanced stage disease and correlated
with decreased disease-specific survival [19]. In breast cancer
serum IL-6 levels were significantly higher than in a control
group of healthy women [20]. Thus IL-6 produced from
tumor cells may be a pathophysiologic trigger of tumor-
induced thrombocytosis across different cancer types in a
manner similar to that proposed for ovarian cancer [13].
The mechanistic basis of platelets contribution to car-
cinogenesis is a subject of study [21]. Circulating tumor cells
may use platelets as a shield to protect themselves from the
attack of the immune system and as an intermediary helping
them to attach to endothelial cells at the destination sites
of metastases. In addition heteroaggregates constituted of
platelets and tumor cells may embolize in the microcircu-
lation and aid in the process of extravasation of tumor cells
in metastatic sites. Platelets have also roles in carcinogenesis
directly related to their normal function in promotion of
vascular integrity [22]. Newly formed tumor vasculature is
particularly prone to dysfunction, and platelets have been
shown to be indispensable for preventing hemorrhage in
tumor beds [23]. Platelets are carriers in their granules
of a plethora of bioactive molecules and growth factors.
These include Vascular Endothelial Growth Factor (VEGF),
Epidermal Growth Factor (EGF), Platelet-Derived Growth
Factor (PDGF), Hepatocyte Growth Factor (HGF), Insulin-
like Growth Factor (IGF), Transforming Growth Factor
𝛽 (TGF𝛽), Interleukin 1𝛽 (IL-1𝛽), IL-8, CXC motif con-
taining ligand 12 (CXCL12), Sphingosine-1-phosphate (S1P),
and lysophosphatidic acid among others [24, 25]. Each of
these factors may actively contribute to metastatic tumor
progression. Platelet-derived TGF𝛽, for example, promotes
an EMT (epithelial to mesenchymal transition) program in
tumor cells through Smad and NF-𝜅B signaling in these
cells [26]. EMT is a program that endows epithelial cells
with a mesenchymal phenotype that promotes mobility and
metastasis while protecting them from anoikis (apoptosis due
to lack of adhesion) [27]. Platelets from patients with cancer
have a higher VEGF level than platelets from individuals
without cancer [28]. In contrast circulating VEGF is not
elevated in cancer patients except in renal cell carcinoma
if care is taken to avoid artificial platelet activation during
venipuncture [28]. As a result platelet counts may better
reflect VEGF concentrations in the tumor and metastases
sites environment where they are activated and contribute to
tumor angiogenesis.
In conclusion, this retrospective analysis of a series of
metastatic breast cancer patients shows that thrombocytosis
(defined in this paper as platelets more than 350 × 109/L)
at the time of diagnosis of metastatic disease has prognos-
tic value regarding overall and progression free survival.
The presence of thrombocytosis is independent of biologic
characteristics that help classify breast cancer to subgroups
relevant for treatment such as ER/PR and Her-2 expression
and thus has value beyond these characteristics. Further study
is needed in more extensive series to confirm these results
and especially to test whether thrombocytosis can serve as a
predictive marker of specific treatments. In this respect and
in view of the above discussion it would be of particular
interest to test thrombocytosis as a predictive marker of anti-
VEGF therapies. Indeed a recent study inmetastatic renal cell
carcinoma has shown that patients with thrombocytosis had
a higher risk to present a primary refractoriness to anti-VEGF
treatments (odds ratio = 1.7, 𝑃 = 0.0068) than patients with
normal platelets [29]. It remains to be seen if thrombocytosis
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could be a predictive factor for anti-VEGF therapies in other
cancers and in breast cancer in particular.
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